POZ - CROI 2014 - Conference on Retroviruses and Opportunistic Infections - HIV - AIDS - Hepatitis

POZ - Health, Life and HIV
Subscribe to:
POZ magazine
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr MySpace
POZ Personals
Sign In / Join
What you need to know
> Blogs > POZ TV > Treatment News > POZ Exclusives > Opinion

Virus-Free After PrEP and Conventional Treatment

Man who contracted HIV perhaps five days before starting regime shows no sign of virus several months later.

ZFN Technology

Genetically modifying cells to resist HIV shows promise.

Aggressive Treatment

A second baby born with HIV is now apparently HIV negative.

A Blow to HIV Cure Research

Failure to awaken dormant cells creates disappointment for HIV cure research.

PrEP Quarterly

Early trial raises hopes of pre-exposure prophylaxis injections every three months.

PrEP Monthly

Monthly pre-exposure prophylaxis injections show promise in female monkeys.

Cancer Warning

Common cancers are more fatal among people with HIV.

Close to Zero

Viral suppression may eliminate HIV transmission risk.

CROI 2014
Kicks Off

Annual conference brings together researchers from around the world to share the latest studies.

Coverage from
AIDSmeds & POZ

Treating HIV Very Early May Limit Inflammation, Gut Damage

Daclatasvir/Olysio Combo Effectively Treats Hep C Genotype 1b

Failure to Awaken Dormant Cells Deals Blow to HIV Cure Research

PrEP Adherence Varies Greatly Between Cities

Crystal Meth May Fuel HIV Disease Progression and Transmission

Male Circumcision Lowers HIV Rates in Women as Well

Man Who Began HIV Treatment 5 Days In Appears Virus-Free

Sovaldi & Ribavirin Is Effective for HIV/HCV Population

Viread During Pregnancy Lowers Babies’ Bone Density

BMS’s Attachment Inhibitor Shows Promise

Very Early HIV Treatment in Monkeys Limits Viral Reservoir

Isentress + Prezista Is Safe, Effective as First-Line HIV Therapy

Common Cancers Are More Fatal Among People With HIV

HIV-Positive Men’s Risk of Heart Attack May Be Dropping

Two in Five Gay Men ‘Serosort’ in an Attempt to Prevent HIV

HIV Meds Greatly Benefit South Africans, But Favor Women

Two Studies Raise Hopes for Female-Empowered HIV Prevention

Early Trial Paves the Way for Study of Long-Acting HIV Meds

High HCV Cure Rates for BMS Set Stage for Triple Combo Pill

Merck’s Hep C Drugs Show Promise for HIV Coinfection

Gilead’s Combo Therapy Cures Hep C in Just Six Weeks

99% Cure Rates for AbbVie’s Hep C Combo in Genotype 1b

Genetic HIV Therapy Aided by Drug to Boost CD4 Infusion

Young Black Gays in Atlanta Getting HIV at Breakneck Pace

Viral Suppression May Bring HIV Transmission Risk Close to Zero

A Second Baby Born With HIV Is Now Apparently HIV Negative

Early Trial Raises Hopes of Quarterly PrEP Injections

Genetically Modifying Cells to Resist HIV Shows Promise

Monthly PrEP Injections Show Promise in Female Monkeys

More MSM Get Tested for HIV, and More of Them Take Meds

> More Newsfeed
Footage from the conference
A roundtable discussion by IFARA/AccessHIV.
> More POZ TV

20th Conference on Retroviruses and Opportunistic Infections (CROI 2013)
Atlanta, GA
March 3 - 7, 2013

19th Conference on Retroviruses and Opportunistic Infections (CROI 2012)
Seattle, WA
March 5 - 8, 2012

18th Conference on Retroviruses and Opportunistic Infections (CROI 2011)
Boston, MA
February 27 - March 2, 2011

more conference coverage
[ about Smart + Strong | about POZ | POZ advisory board | partner links | advertising policy | advertise/contact us | site map]
© 2016 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.